Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs.

Jessica J. Lin,Adam J. Schoenfeld,Viola W. Zhu,Beow Y. Yeap,Emily Chin,Marguerite Rooney,Andrew J. Plodkowski,Subba R. Digumarthy,Ibiayi Dagogo-Jack,Justin F. Gainor,Sai-Hong Ignatius Ou,Gregory J. Riely,Alice T. Shaw

Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs.

2019

Jessica J. Lin
Adam J. Schoenfeld
Viola W. Zhu
Beow Y. Yeap
Emily Chin
Marguerite Rooney
Andrew J. Plodkowski
Subba R. Digumarthy
Ibiayi Dagogo-Jack
Justin F. Gainor
Sai-Hong Ignatius Ou
Gregory J. Riely
Alice T. Shaw

9067Background: Second-generation (gen) ALK tyrosine kinase inhibitors (TKIs) are standard first- and second-line therapies in patients (pts) with advanced ALK+ non-small cell lung cancer (NSCLC). ...

Keywords:

Lung cancer
Pathology
Medicine
Cell
Refractory
Cancer research
Pemetrexed
Tyrosine kinase
Chemotherapy
non small cell
combination chemotherapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations